FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 18, 2020

NeuroBo Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-37809
(Commission
File Number)

47-2389984
(IRS Employer
Identification No.)

200 Berkeley Street, 19th Floor
Boston, Massachusetts
(Address of principal executive offices)

02116
(Zip Code)

Registrant’s telephone number, including area code: (857) 702-9600

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, par value $0.001 per share</td>
<td>NRBO</td>
<td>The Nasdaq Stock Market, LLC</td>
</tr>
</tbody>
</table>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
At the annual meeting (the “Annual Meeting”) of stockholders of NeuroBo Pharmaceuticals, Inc. (the “Company”) on June 18, 2020, the Company’s stockholders elected two Class I directors to the Company’s Board of Directors, each to serve three-year terms until the 2023 annual meeting of stockholders and ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

At the Annual Meeting, the total number of shares represented in person or by proxy was 13,894,500 of the 16,427,307 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting as of the April 20, 2020 record date.

The voting results at the Annual Meeting are shown below:

### Proposal 1—Election of Directors

<table>
<thead>
<tr>
<th>Class I Nominees</th>
<th>Votes For</th>
<th>Votes Withheld</th>
<th>Broker Non-Votes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Steven Gullans</td>
<td>13,616,802</td>
<td>10,474</td>
<td>267,224</td>
</tr>
<tr>
<td>Ms. Irene Kim</td>
<td>13,625,646</td>
<td>1,630</td>
<td>267,224</td>
</tr>
</tbody>
</table>

### Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm

<table>
<thead>
<tr>
<th></th>
<th>Votes For</th>
<th>Votes Against</th>
<th>Votes Abstain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>13,891,383</td>
<td>1,383</td>
<td>1,734</td>
</tr>
</tbody>
</table>
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEUROBO PHARMACEUTICALS, INC.

Date: June 18, 2020

By: /s/ Richard Kang

Richard Kang
President and Chief Executive Officer